Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL573556 | 0.92 | KDM4E (0.33) | KDM4EALDH1A1MAPTBLMCNR2 | |
| SCHEMBL23966709 | 0.92 | KDM4E (0.33) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL23966775 | 0.84 | KDM4E (0.33) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL25831470 | 0.82 | KDM4E (0.30) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL24410809 | 0.81 | KDM4E (0.32) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL16590521 | 0.77 | SLC6A2 (0.38) | KDM4EALDH1A1MAPTCNR2 | |
| SCHEMBL23982644 | 0.76 | KDM4E (0.30) | KDM4EALDH1A1MAPTBLM | |
| SCHEMBL4007416 | 0.75 | NOTUM (0.43) | — | |
| SCHEMBL13391770 | 0.74 | — | — | |
| SCHEMBL25799350 | 0.73 | SMN1; SMN2 (0.35) | ALDH1A1MAPTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
| EP-4240738-B1 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | LILLY CO ELI (US) | 2025-05-07 | — | — | EP | disclosed |
| US-11970485-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| US-20230265085-A1 | RET KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| CN-116438179-A | Pyrazole derivatives as RET kinase inhibitors | 伊莱利利公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11697647-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
| EP-0129928-B1 | OXAZOLYL-SUBSTITUTED DIAZAHETEROCYCLES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-09-02 | — | — | EP | disclosed |
| EP-0129928-A1 | Oxazolyl-substituted diazaheterocycles | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970485-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | KDM4E 1642/4885ALDH1A1 1205/4885MAPT 2324/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | KDM4E 1778/4885ALDH1A1 4354/4885MAPT 1210/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | KDM4E 4052/4885ALDH1A1 4542/4885MAPT 436/4885 |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | KDM4E 2943/4885ALDH1A1 3894/4885MAPT 1938/4885 |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | KDM4E 2973/4885ALDH1A1 2533/4885MAPT 3944/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | KDM4E 2943/4885ALDH1A1 3894/4885MAPT 1938/4885 |
| US-11697647-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | KDM4E 1642/4885ALDH1A1 1205/4885MAPT 2324/4885 |
| US-20230265085-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | KDM4E 1642/4885ALDH1A1 1205/4885MAPT 2324/4885 |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | CDK2, PHKG1, PHKG2 | KDM4E 1253/4885ALDH1A1 3736/4885MAPT 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.